Every Form 4 that Cidara Therapeutics, Inc. (CDTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CDTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDTX filings page.
RA Capital Healthcare Fund, advised by RA Capital Management, fully exited its Cidara Therapeutics (CDTX) position in connection with Merck’s acquisition. Pre-funded warrants for 1,286,786 common shares were cashless exercised into common stock immediately before the merger. The Fund then disposed of 4,652,309 Cidara common shares at $221.50 per share in the tender offer. It also disposed of 89,956 Series A Preferred shares, which were exchanged for $15,505.00 per Series A share under the merger terms.
Outstanding stock options covering 22,200 and 5,079 common shares became fully vested and were cancelled at the merger’s effective time in return for cash based on the $221.50 per-share merger price minus the applicable exercise prices. The Form 4 notes that the reported securities are held by the Fund and that RA Capital entities and principals disclaim beneficial ownership except for their pecuniary interests.
Cidara Therapeutics director reports option cancellation tied to Merck buyout. On January 7, 2026, a Merck subsidiary completed a tender offer for all outstanding Cidara common and Series A preferred shares and then merged into Cidara, which continues as a wholly owned Merck subsidiary. In connection with the merger, each outstanding stock option became fully vested and, if unexercised, was cancelled at the merger’s effective time and converted into a cash right equal to the number of underlying shares multiplied by the excess of $221.50 per share over the option’s exercise price.
The Form 4 reports that director Joshua Resnick had stock options covering 22,200 and 5,079 Cidara common shares, both reported as derivative dispositions leaving zero options outstanding. The filing notes these options are held for the benefit of RA Capital Healthcare Fund, and Resnick is required to turn over any net cash or stock to RA Capital Management, so he disclaims beneficial ownership of the options and underlying shares.
Cidara Therapeutics director Spencer Ryan reported the cash-out of his stock options in connection with Merck’s acquisition of the company. Under a Merger Agreement dated November 13, 2025 among Cidara, Merck Sharp & Dohme LLC and Caymus Purchaser, Inc., a tender offer for all outstanding common and Series A preferred shares was completed on January 7, 2026 and followed by a merger, making Cidara a wholly owned subsidiary of Merck.
Immediately before the effective time of the merger, each of Ryan’s outstanding stock options became fully vested and exercisable and, to the extent unexercised, was cancelled and converted into a right to receive cash. The cash amount equals the number of common shares subject to each option multiplied by the excess of $221.50 per share over the option’s exercise price. The Form 4 lists option grants with exercise prices of $12.63, $12.64 and $21.31 per share, all reduced to zero balance after the transaction.
Cidara Therapeutics director James Merson reported the cash cancellation of stock options tied to Merck’s acquisition of Cidara. On January 7, 2026, a Merck subsidiary completed a tender offer for all outstanding Cidara common shares and Series A preferred shares and then merged into Cidara, which became a wholly owned Merck subsidiary. In connection with the merger, each of Merson’s outstanding stock options, including grants over 4,250, 2,125 and 11,100 Cidara common shares, became fully vested and exercisable and was then cancelled.
Each cancelled option was converted into the right to receive cash, without interest and subject to tax withholding, equal to the number of underlying shares multiplied by the excess of $221.50 per share over the option’s exercise price.
Cidara Therapeutics director Carin Canale-Theakston reported the cash-out of stock options in connection with Cidara’s acquisition by Merck. On January 7, 2026, a Merck subsidiary completed a tender offer for all outstanding Cidara common and Series A preferred shares and then merged into Cidara, which became a wholly owned Merck subsidiary.
Immediately before the merger became effective, each of the director’s outstanding stock options became fully vested and exercisable, then was cancelled at the effective time and converted into the right to receive cash. The cash amount for each option equals the number of common shares subject to the option multiplied by the excess of $221.50 per share over the option’s exercise price. The reported option grants, which had exercise prices ranging from $10.6 to $50.2 and various expiration dates from 2031 to 2035, now show 0 derivative securities owned following these transactions. All exercise prices and share amounts were adjusted for Cidara’s 1-for-20 reverse stock split on April 24, 2024.
Cidara Therapeutics director Bonnie L. Bassler reported the cash-out of her remaining equity as Cidara was acquired by Merck. On January 7, 2026, a Merck subsidiary completed a tender offer and merger in which each Cidara common share was converted into the right to receive $221.50 in cash and each Series A preferred share into $15,505.00 in cash, both without interest and subject to withholding taxes. Bassler disposed of 15 common shares at $221.50 per share and all reported stock options were canceled at the merger’s effective time in exchange for cash based on the spread between $221.50 and each option’s exercise price. All amounts reflect a 1-for-20 reverse stock split completed on April 24, 2024.
Cidara Therapeutics director Chrysa Mineo reported the cash-out of her equity in connection with Merck’s acquisition of the company. On January 7, 2026, a Merck subsidiary completed a tender offer and merger that turned Cidara into a wholly owned Merck subsidiary. Each common share and Series A preferred share was converted into the right to receive cash.
Mineo disposed of 3,320 common shares at $221.50 per share, leaving her with no directly held common stock. Multiple stock options to buy Cidara common shares, with exercise prices adjusted for a prior 1‑for‑20 reverse split, were also fully vested and then canceled at the merger’s effective time. Each option was converted into a cash right equal to the number of shares underlying the option multiplied by the excess of $221.50 over the option’s exercise price.
Cidara Therapeutics director reports option cancellation in Merck buyout
Director Theodore R. Schroeder reported the disposition of multiple stock options for Cidara Therapeutics, Inc. on January 7, 2026. According to the disclosed merger agreement, Merck Sharp & Dohme LLC, through a subsidiary, completed a tender offer for all outstanding common and Series A preferred shares of Cidara and then merged the subsidiary into Cidara, which continues as a wholly owned subsidiary of Merck.
Immediately prior to and contingent upon the effective time of the merger, each outstanding option became fully vested and exercisable and, to the extent it remained unexercised, was cancelled and converted into a right to receive cash. The cash amount for each option equals the number of common shares subject to the option multiplied by the excess of $221.50 per share over the option’s exercise price, with all derivative positions reported in this filing reduced to zero after the transactions.
Cidara Therapeutics director Daniel D. Burgess reported the disposition of his remaining equity in the company on January 7, 2026, in connection with the completion of Merck’s acquisition of Cidara. A total of 150 shares of common stock, held indirectly through his spouse, were disposed of at $221.50 per share, leaving no common shares reported as beneficially owned.
The filing also shows that multiple stock options covering various amounts of Cidara common shares were fully vested and then canceled at the merger effective time, with each option converted into a cash payment equal to its intrinsic value based on the $221.50 per share merger consideration. All option positions are reported at 0 following these transactions. The share and option figures reflect a 1‑for‑20 reverse stock split effected on April 24, 2024.
Cidara Therapeutics President & CEO Jeffrey Stein reported the disposition of all his Cidara securities in connection with Merck’s acquisition of the company. On January 7, 2026, common shares held directly, and indirectly through his son and a trust, were tendered and converted into the right to receive $221.50 per common share in cash under the merger terms.
The filing also shows that all of Stein’s employee stock options, covering various numbers of common shares at different exercise prices, were cancelled at the effective time of the merger and converted into cash based on the excess of $221.50 per share over each option’s exercise price. All reported positions show 0 shares or options remaining, reflecting Cidara’s completion of the merger as a wholly owned subsidiary of Merck.
Cidara Therapeutics Chief Financial Officer Frank Karbe reported the cash-out of his equity holdings in connection with Merck’s acquisition of the company. On January 7, 2026, he disposed of 7,526 shares of Cidara common stock at $221.50 per share in the tender offer and merger, and a further 43,125 shares were reduced to zero balance as they were converted into the right to receive cash.
The filing also shows 115,000 employee stock options were cancelled on January 7, 2026 and converted into cash based on the spread between the $221.50 merger price and their exercise price. Under the Merger Agreement, all outstanding common shares were exchanged for $221.50 per share and all Series A preferred shares for $15,505.00 per share in cash, and Cidara became a wholly owned subsidiary of Merck.
Cidara Therapeutics, Inc. completed its sale to Merck, with all outstanding common and Series A preferred shares acquired under a merger agreement dated November 13, 2025. On January 7, 2026, each common share was exchanged for $221.50 in cash and each Series A preferred share for $15,505.00 in cash, both without interest and subject to withholding taxes.
COO & CLO Shane Ward reported the disposition of 25,083 common shares at $221.50 per share, leaving no directly held common stock. Multiple employee stock options covering various numbers of common shares and exercise prices were also fully vested and then cancelled at the merger’s effective time, with each option converted into a cash right equal to the number of underlying shares multiplied by the excess of $221.50 over the option exercise price.
Cidara Therapeutics, Inc. Chief Medical Officer Nicole Negar Davarpanah reported the cash-out of her equity holdings in connection with the company’s merger with Merck Sharp & Dohme LLC. On January 7, 2026, a Merck subsidiary completed a tender offer and subsequent merger, making Cidara a wholly owned Merck subsidiary.
Under the Merger Agreement, each Cidara common share was exchanged for $221.50 per share in cash, and each Series A preferred share for $15,505.00 per share in cash, both without interest and subject to tax withholding. The filing shows dispositions of common stock at $221.50 per share, and the cancellation of restricted stock units and employee stock options in exchange for cash based on the $221.50 common share value, less any applicable option exercise prices. Following these transactions, the reporting person no longer holds Cidara common stock or options.
Cidara Therapeutics’ President & CEO Jeffrey Stein, a director of the company, filed an updated Form 4 covering historical transactions in Cidara common stock. The filing restates prior reports from 2016, 2017, 2020 and 2021 to correct how many shares were shown as beneficially owned by him and to reclassify certain purchases as made by a trust rather than directly by him. All share and price figures in the table have been adjusted for the company’s 1‑for‑20 reverse stock split effected on April 24, 2024.
The filing also reports a gift of common stock on December 31, 2021 from Stein to his sons, with shares held both by a trust and by a son. The disclosure notes that he disclaims beneficial ownership of the shares held by his independent son, and states that the report should not be taken as an admission that he is the beneficial owner of those shares for Section 16 or any other purpose.
Cidara Therapeutics, Inc. reported an insider stock transfer by its Chief Medical Officer on a Form 4. On 12/29/2025, the officer made a bona fide gift of 450 shares of common stock to a donor-advised fund for charitable purposes, with no beneficial ownership or control retained over the donated shares. Following this transaction, the officer beneficially owns 20,886 shares of Cidara common stock, which includes 50 shares acquired through the company’s Employee Stock Purchase Plan on December 18, 2025.
Cidara Therapeutics’ Chief Financial Officer reported a change in ownership of company common stock. On December 10, 2025, a transaction coded “F” involved 7,290 shares of common stock at $219.6 per share, identified as shares withheld to satisfy taxes upon RSU vesting.
Following this transaction, the officer directly owned 50,562 shares of Cidara Therapeutics common stock. This amount includes 352 shares acquired through the company’s Employee Stock Purchase Plan on November 20, 2025.
Cidara Therapeutics reported insider stock transactions by its COO & CLO. On December 10, 2025, 15,041 common shares were withheld to cover taxes on restricted stock unit vesting at $219.6 per share. The officer exercised employee stock options to purchase 3,500 shares at $16.654 and 6,459 shares at $20.2, and sold 9,959 shares at $220.077 per share. Following these transactions, the officer directly owned 25,033 common shares, including 400 acquired through the employee stock purchase plan, and held 6,207 stock options, with all share amounts adjusted for a 1-for-20 reverse stock split effective April 24, 2024.
Cidara Therapeutics’ Chief Medical Officer reported a routine insider stock transaction. On 12/10/2025, 10,332 shares of common stock were disposed of to cover taxes due on restricted stock unit vesting, as explained in the footnotes. After this tax withholding, the officer beneficially owned 21,286 common shares directly, which includes 200 shares acquired through the company’s Employee Stock Purchase Plan on November 20, 2025.